Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Rheumatology Reports
Published in: Current Rheumatology Reports 9/2017

01-09-2017 | Vasculitis (L Espinoza, Section Editor)

Pulmonary Involvement in Systemic Vasculitis

Authors: Luis Felipe Flores-Suárez, Marco A. Alba, Heidegger Mateos-Toledo, Natllely Ruiz

Published in: Current Rheumatology Reports | Issue 9/2017

Login to get access

Abstract

Purpose of Review

The purpose of this study is to describe the most relevant advances concerning lung involvement in the ANCA-associated vasculitides (excluding eosinophilic granulomatosis with polyangiitis which may have different disease mechanisms). Focus is on pathophysiology, recent important imagenological procedures, treatment, and outcome.

Recent Findings

Emerging information exists on potential newly investigated diagnostic procedures (v.g. transbronchial cryobiopsies), detailed tomographic abnormalities, the potential favorable role of rituximab and the still uncertain one of plasma exchange in the treatment, and the increasing description of interstitial lung disease. Survival is reduced in case of both, diffuse alveolar hemorrhage and diffuse parenchymal disease.

Summary

There is the need to expand the knowledge concerning better long-term treatment options with specific regimes, and to incorporate other measures regarding integral treatment in patients afflicted with lung involvement these maladies, as the outcome seems adverse in this scenario.
Literature
1.
Jennette JC, Falk RJ, Bacon PA, et al. 2012 Revised international Chapel Hill consensus conference nomenclature of vasculitides. Arthritis Rheum. 2013;65:1–11.CrossRefPubMed
2.
Watts RA, Mahr A, Mohammad AJ, et al. Classification, epidemiology and clinical subgrouping of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Nephrol Dial Transplant. 2015;30(Suppl 1):i14–22.CrossRefPubMed
3.
Fujimoto S, Watts RA, Kobayashi S, et al. Comparison of the epidemiology of anti-neutrophil cytoplasmic antibody-associated vasculitis between Japan and the U.K. Rheumatology. 2011;50:1916–20.CrossRefPubMed
4.
Roth AJ, Ooi JD, Hess JJ, et al. Epitope specificity determines pathogenicity and detectability in ANCA-associated vasculitis. J Clin Invest. 2013;123:1773–83.CrossRefPubMedPubMedCentral
5.
Kim YC, Choi YS, Alam J, et al. Induction of proteinase 3-anti-neutrophil cytoplasmic autoantibodies by proteinase 3-homologous bacterial protease in mice. Immunol Res. 2016;64:438–44.CrossRefPubMed
6.
7.
8.
• Merkel PA, Xie G, Monach PA, et al. Identification of functional and expression polymorphisms associated with risk for anti-neutrophil cytoplasmic autoantibody-associated vasculitis. Arthritis Rheumatol. 2017;69:1054–66. A study which ratified the findings of the large European GWAS study (previous reference). CrossRefPubMedPubMedCentral
9.
Ciavatta DJ, Yang J, Preston GA, et al. Epigenetic basis for aberrant upregulation of autoantigen genes in humans with ANCA vasculitis. J Clin Invest. 2010;120:3209–19.CrossRefPubMedPubMedCentral
10.
Abdgawad M, Gunnarsson L, Bengtsson AA, et al. Elevated neutrophil membrane expression of proteinase 3 is dependent upon CD177 expression. Clin Exp Immunol. 2010;161:89–97.PubMedPubMedCentral
11.
Komocsi A, Lamprecht P, Csernok E, et al. Peripheral blood and granuloma CD4(+)CD28(−) T cells are a major source of interferon-gamma and tumor necrosis factor-alpha in Wegener’s granulomatosis. Am J Pathol. 2002;160:1717–24.CrossRefPubMedPubMedCentral
12.
Rimbert M, Hamidou M, Braudeau C, et al. Decreased numbers of blood dendritic cells and defective function of regulatory T cells in antineutrophil cytoplasmic antibody-associated vasculitis. PLoS One. 2011;6:e18734.CrossRefPubMedPubMedCentral
13.
Free ME, Bunch DO, McGregor JA, et al. Patients with antineutrophil cytoplasmic antibody-associated vasculitis have defective Treg cell function exacerbated by the presence of a suppression-resistant effector cell population. Arthritis Rheum. 2013;65:1922–33.CrossRefPubMed
14.
Ooi JD, Chang J, Hickey MJ, et al. The immunodominant myeloperoxidase T-cell epitope induces local cell-mediated injury in antimyeloperoxidase glomerulonephritis. Proc Natl Acad Sci U S A. 2012;109:E2615–24.CrossRefPubMedPubMedCentral
15.
Bunch DO, McGregor JG, Khandoobhai NB, et al. Decreased CD5(+) B cells in active ANCA vasculitis and relapse after rituximab. Clin J Am Soc Nephrol. 2013;8:382–91.CrossRefPubMedPubMedCentral
16.
Xiao H, Hu P, Falk RJ, Jennette JC. Overview of the pathogenesis of ANCA-associated vasculitis. Kidney Dis (Basel). 2016;1:205–15.CrossRef
17.
Holden NJ, Williams JM, Morgan MD, et al. ANCA-stimulated neutrophils release BLyS and promote B cell survival: a clinically relevant cellular process. Ann Rheum Dis. 2011;70:2229–33.CrossRefPubMed
18.
Porges AJ, Redecha PB, Kimberly WT, et al. Anti-neutrophil cytoplasmic antibodies engage and activate human neutrophils via Fc gamma RIIa. J Immunol. 1994;153:1271–80.PubMed
19.
Schönermarck U, Csernok E, Gross WL. Pathogenesis of anti-neutrophil cytoplasmic antibody-associated vasculitis: challenges and solutions 2014. Nephrol Dial Transplant. 2015;30(Suppl 1):i46–52.PubMed
20.
Ewert BH, Jennette JC, Falk RJ. Anti-myeloperoxidase antibodies stimulate neutrophils to damage human endothelial cells. Kidney Int. 1992;41:375–83.CrossRefPubMed
21.
Little MA, Smyth L, Salama AD, et al. Experimental autoimmune vasculitis: an animal model of anti-neutrophil cytoplasmic autoantibody-associated systemic vasculitis. Am J Pathol. 2009;174:1212–20.CrossRefPubMedPubMedCentral
22.
Xiao H, Heeringa P, Hu P, et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest. 2002;110:955–63.CrossRefPubMedPubMedCentral
23.
Mueller A, Holl-Ulrich K, Lamprecht P, Gross WL. Germinal centre-like structures in Wegener’s granuloma: the morphological basis for autoimmunity? Rheumatology. 2008;47:1111–3.CrossRefPubMed
24.
Hu P, Xiao H, Alba MA, Falk RJ, Jennette JC. Anti-MPO antibodies cause granulomatosis in mice: an animal model of GPA. Rheumatology 2017;56 (suppl. 3):iii29. Abstract WS6_1. The 18th International Vasculitis & ANCA Workshop 2017.
25.
Thickett DR, Richter AG, Nathani N, et al. Pulmonary manifestations of anti-neutrophil cytoplasmic antibody (ANCA)-positive vasculitis. Rheumatology. 2006;45:261–8.CrossRefPubMed
26.
Ravindran V, Watts RA. Pulmonary haemorrhage in ANCA associated vasculitis. Rheumatology. 2010;49:1410–2.CrossRefPubMed
27.
Lichtenberger JP, Digumarthy SR, Abbott GF, et al. Diffuse pulmonary hemorrhage: clues to the diagnosis. Curr Probl Diagn Radiol. 2014;43:128–39.CrossRefPubMed
28.
•• Yamagata M, Ikeda K, Tsushima K, et al. Prevalence and responsiveness to treatment of lung abnormalities on chest computed tomography in patients with microscopic polyangiitis: a multicenter, longitudinal, retrospective study of one hundred fifty consecutive hospital-based Japanese patients. Arthritis Rheumatol. 2016;68:713–23. A very informative study concerning the detailed imagenological findings in MPA and their changes according to treatment. CrossRefPubMed
29.
30.
Lally L, Spiera F. Pulmonary vasculitis. Rheum Dis Clin N Am. 2015;41:315–31.CrossRef
31.
• Ussavarungsi K, Kern R, Anja C, et al. Transbronchial cryobiopsy in diffuse parenchymal lung disease: retrospective analysis of 74 cases. Chest. 2017;151:400–8. An article describing a recent technique to obtain adequate samples in diffuse lung parenchymal disease from different etiologies. CrossRefPubMed
32.
Mahmoud S, Ghosh S, Farver C, et al. Pulmonary vasculitis: spectrum of imaging appearances. Radiol Clin N Am. 2016;54:1097–118.CrossRefPubMed
33.
Castañer E, Alguersuari A, Andreu M, et al. Imaging findings in pulmonary vasculitis. Semin Ultrasound CT MR. 2012;33:567–79.CrossRefPubMed
34.
• Ikeda S, Arita M, Misaki K, et al. Comparative investigation of respiratory tract involvement in granulomatosis with polyangiitis between PR3-ANCA positive and MPO-ANCA positive cases: a retrospective cohort study. BMC Pulm Med. 2015;15:78. Important study from Japan in where many GPA patients are MPO-ANCA positive, and poses the question regarding clinical classification versus serotyping as a more accurate discrimination tool. CrossRefPubMedPubMedCentral
35.
36.
•• Kagiyama N, Takayanagi N, Kanauchi T, et al. Antineutrophil cytoplasmic antibody-positive conversion and microscopic polyangiitis development in patients with idiopathic pulmonary fibrosis. BMJ Open Resp Res. 2015;2:e000058. A relevant article which describes that some patients with IPF can evolve to MPA, and the influence of GC treatment (or not) in possibly evolving to that endpoint. CrossRefPubMedPubMedCentral
37.
Ando M, Miyazaki E, Ishii T, et al. Incidence of myeloperoxidase anti-neutrophil cytoplasmic antibody positivity and microscopic polyangitis in the course of idiopathic pulmonary fibrosis. Respir Med. 2013;107:608–15.CrossRefPubMed
38.
Homma S, Suzuki A, Sato K. Pulmonary involvement in ANCA-associated vasculitis from the view of the pulmonologist. Clin Exp Nephrol. 2013;17:667–71.CrossRefPubMed
39.
•• Comarmond C, Crestani B, Tazi A, et al. Pulmonary fibrosis in antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis. A series of 49 patients and review of the literature. Medicine. 2014;93:340–9. The largest up to date single center study regarding this complication in patients with AAV. CrossRefPubMedPubMedCentral
40.
• Iftikhar IH, Alghothani L, Sardi A, et al. Transbronchial lung cryobiopsy and video-assisted lung thorachoscopic lung biopsy in the diagnosis of diffuse parenchymal disease: e meta-analysis of diagnostic test accuracy. Ann Am Thorac Soc. 2017; doi:10.​1513/​AnnalsATS.​201701-086SR. This metaanalysis secures the safety of transbronchial lung biopsies versus video-assisted thoracoscopic tissue obtainment, with similar diagnostic accuracy in diffuse lung diseases.
41.
42.
Specks U, Merkel PA, Seo P, et al. Efficacy of remission-induction regimens for ANCA-associated vasculitis. New Engl J Med. 2013;369:417–27.CrossRefPubMed
43.
• Miloslavsky EM, Specks U, Merkel PA, et al. Rituximab for the treatment of relapses in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol. 2014;66:3151–9. Retreatment with RTX in relapsing patients is safe and probably a better option than other treatments, in patients previously treated with CYC or RTX. CrossRefPubMedPubMedCentral
44.
•• Cartin-Ceba R, Diaz-Caballero L, Al-Qadi MO, et al. Diffuse alveolar hemorrhage secondary to antineutrophil cytoplasmic antibody-associated vasculitis. Predictors of respiratory failure and clinical outcomes. Arthritis Rheumatol. 2016;68:1467–76. The most comprehensive up to date study of alveolar hemorrhage in the context of AAV. It details important points to be considered regarding outcome and therapy. CrossRefPubMed
45.
Holle JU, Dubrau C, Herlyn K, et al. Rituximab for refractury granulomatosis with polyangiitis (Wegener’s granulomatosis): comparison of efficacy in granulomatous versus vasculitic manifestations. Ann Rheum Dis. 2012;71:327–33.CrossRefPubMed
46.
de Groot K, Rasmussen N, Bacon PA, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody associated-vasculitis. Arthritis Rheum. 2005;52:2461–9.CrossRefPubMed
47.
•• Guillevin L, Pagnoux C, Karras A, et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med. 2014;371:1771–80. A seminal study regarding RTX treatment for remission maintenance in AAV as compared to the standard for this indication since 1993. CrossRefPubMed
48.
Hirayama K, Kobayashi M, Usui J, et al. Pulmonary involvements of anti-neutrophil cytoplasmic autoantibody-associated renal vasculitis in Japan. Nephrol Dial Transplant. 2015;30:i83–93.PubMed
49.
Homma S, Matsushita H, Nakata K. Pulmonary fibrosis in myeloperoxidase antineutrophil cytoplasmic antibody-associated vasculitides. Respirology. 2004;9:190–6.CrossRefPubMed
50.
Flores-Suárez LF, Ruiz N, Saldarriaga Rivera LM, et al. Reduced survival in microscopic polyangiitis patients with pulmonary fibrosis in a respiratory center. Clin Rheumatol. 2015;34:1653–4.CrossRefPubMed
Metadata
Title
Pulmonary Involvement in Systemic Vasculitis
Authors
Luis Felipe Flores-Suárez
Marco A. Alba
Heidegger Mateos-Toledo
Natllely Ruiz
Publication date
01-09-2017
Publisher
Springer US
Published in
Current Rheumatology Reports / Issue 9/2017
Print ISSN: 1523-3774
Electronic ISSN: 1534-6307
DOI
https://doi.org/10.1007/s11926-017-0682-4

Other articles of this Issue 9/2017

Current Rheumatology Reports 9/2017 Go to the issue

Spondyloarthritis (M Khan, Section Editor)

Mechanism of New Bone Formation in Axial Spondyloarthritis

Complementary and Alternative Medicine (S Kolasinski, Section Editor)

Mindfulness Meditation for Fibromyalgia: Mechanistic and Clinical Considerations

Health Economics and Quality of Life (N Tsao, Section Editor)

Do Biologic Therapies for Rheumatoid Arthritis Offset Treatment-Related Resource Utilization and Cost? A Review of the Literature and an Instrumental Variable Analysis

Chronic Pain (R Staud, Section Editor)

Predictors of Osteoarthritis Pain: the Importance of Resilience

Osteoarthritis (M Goldring, Section Editor)

Wnt/β-catenin Signaling in Osteoarthritis and in Other Forms of Arthritis

Systemic Lupus Erythematosus (G Tsokos, Section Editor)

Epigenetics in SLE
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits